32 results
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
and extensive Phase 3 clinical trials.
For each clinical trial, an independent IRB or independent ethics committee, covering each site proposing to conduct
424B5
SLNO
Soleno Therapeutics Inc
27 Sep 23
Prospectus supplement for primary offering
5:26pm
rigorous and extensive Phase 3 clinical trials.
For each clinical trial, an independent IRB or independent ethics committee, covering each site proposing
8-K
EX-99.1
qsf8sx6pkpot
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-99.1
lpxono
3 Oct 22
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of
9:00am
424B5
1b9fe9vc1 pwf
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
oahpamq5
28 Mar 22
Prospectus supplement for primary offering
4:53pm
424B5
0s28ufmapso9q
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
yjprom3r2 sahf
23 Jun 20
Prospectus supplement for primary offering
4:06pm